How to Read Drug Test Results

The Immunoassay Screen: How the Test Strip Works

The most common drug test used for cannabis and other substances is the lateral flow immunoassay — the type found in both home test kits and the rapid cup tests used in workplace settings. Understanding the underlying biochemical mechanism is essential for correctly reading and interpreting results, because the test’s logic is counterintuitive.

When you consume cannabis, your body metabolizes THC into THC-COOH (11-nor-9-carboxy-THC), a non-psychoactive metabolite stored in fat cells and gradually released into urine. Immunoassay tests use antibodies designed to bind to THC-COOH. The test strip is pre-loaded with drug conjugate — drug molecules attached to a colored label — and two zones: a control zone (C) and a test zone (T).

Here is the counterintuitive competitive binding principle:

• If no drug metabolite is present in the sample, the antibodies have nothing to bind to in solution, so they travel up the strip and bind to the labeled drug conjugate at the test zone — producing a visible test line (T). Combined with the control line, you get two lines = NEGATIVE.
• If drug metabolite is present above the cutoff, it occupies the antibody binding sites in solution, preventing them from reaching the test zone. The T line does not form. Only the control line appears = ONE LINE = POSITIVE.

The control line (C) exists only to confirm that the test is functioning properly. It should always appear regardless of result. If no control line appears, the test is invalid and must be discarded. The test line (T) tells you the actual result.

Faint Lines: What They Mean and What They Do Not Mean

One of the most frequent sources of confusion is a faint test line. Many people interpret a barely visible T line as a near-positive or warning sign that they are close to failing. This is incorrect. Any visible test line, no matter how faint, is classified as a NEGATIVE result under all standard immunoassay interpretive guidelines.

The intensity of the test line is not a quantitative indicator. It simply reflects the amount of antibody-conjugate binding that occurred at the test zone. A faint line means some metabolite was present but at a concentration below the cutoff threshold — that is still a negative result. A very dark line means little or no metabolite was present. The graduation in line darkness does not translate linearly to metabolite concentration in a clinically interpretable way at the point-of-care level.

If you consistently see very faint lines on home tests, you are likely close to the threshold. Re-testing a few days later will tell you more than trying to interpret line intensity. The prudent approach is to wait until you consistently see a clearly visible T line before considering yourself reliably negative.

Cutoff Thresholds: The Numbers That Define a Result

Cutoff thresholds are the numerical backbone of drug test interpretation. They represent the minimum concentration of a specific analyte in the sample that the test is calibrated to detect. Below the cutoff, the result is negative by definition — regardless of whether trace amounts of the metabolite are technically present in the sample at lower concentrations. The cutoff is a regulatory decision, not a pharmacological one.

The practical significance of the two-tier threshold system is important: the initial screen is more sensitive (higher concentration required is actually lower) and less specific, designed to catch everything that might be positive. The confirmatory GC-MS uses a lower cutoff that requires the specific THC-COOH molecule at confirmed concentrations. This means a sample can screen positive but confirm negative — a result that is reported to the employer as overall negative by the MRO.

The GC-MS Confirmation Process

Gas chromatography-mass spectrometry (GC-MS) is the gold standard confirmatory method for drug testing. It operates on entirely different principles than immunoassay and is orders of magnitude more specific. Understanding what GC-MS does helps explain why a positive screen does not equal a failed test.

In the GC step, the urine sample is vaporized and passed through a long capillary column coated with a stationary phase. Different molecules travel through the column at different speeds based on their molecular weight, polarity, and boiling point. THC-COOH emerges from the column at a specific, reproducible retention time. In the MS step, molecules are bombarded with electrons that fragment them into characteristic ionic fragments. The pattern of fragment masses is unique to each compound — a molecular fingerprint. The lab matches the observed fragmentation pattern against a library of known standards. Only an exact match constitutes a confirmed positive.

A cross-reactive compound that fooled the immunoassay antibody cannot produce an identical fragmentation pattern to THC-COOH in the mass spectrometer, because the two compounds are chemically distinct. This is why GC-MS eliminates virtually all cross-reactivity false positives from the initial screen. The reported confirmation accuracy is 97–99% with essentially zero true false positives at the confirmation stage when chain-of-custody procedures are properly followed.

The Medical Review Officer: Your Procedural Safeguard

A confirmed positive GC-MS result does not automatically result in a failed test or adverse employment action. Under SAMHSA and DOT regulations, all confirmed positives in federally mandated testing programs must be reviewed by a licensed Medical Review Officer (MRO) before any result is reported to an employer.

The MRO is a licensed physician with specialized training in substance abuse evaluation and pharmacology. Their role is to act as an independent review layer between the laboratory and the employer, ensuring that legitimate medical explanations are considered before adverse action is taken.

When the laboratory reports a confirmed positive, the MRO contacts the donor directly — before the employer is notified — to conduct a confidential interview. The MRO asks about any prescription medications, over-the-counter drugs, medical conditions, or other factors that could explain the positive result. Common scenarios the MRO considers include: prescribed dronabinol (synthetic THC) for nausea or appetite stimulation, prescribed pain medications that cross-react with opioid screens, or documented medical use in states with medical cannabis programs.

After the interview, the MRO makes one of four determinations:

• Positive: No legitimate medical explanation; result confirmed as positive drug use.
• Negative: A plausible medical explanation exists; result reported as negative to employer.
• Cancelled: An administrative, collection, or laboratory error makes the result unreportable; a new collection may be required.
• Substituted or Adulterated: Specimen validity testing indicates the sample was replaced or tampered with; treated as a refusal to test.

Chain of Custody: Why It Matters for Disputes

Chain of custody (COC) is the documented record of every person who handled the specimen from the moment of collection through laboratory analysis to final reporting. Federal workplace testing programs under DOT/SAMHSA use a standardized federal custody and control form (CCF) that accompanies the specimen at every step. Each transfer is documented with date, time, purpose, and signature.

A break in chain-of-custody — an undocumented transfer, a missing signature, a discrepancy in specimen identifier numbers — can provide grounds to challenge the validity of a result in administrative or legal proceedings. If you are disputing a positive result, obtaining and reviewing the complete chain-of-custody documentation is one of the first steps your attorney will typically take. Any procedural deviation from SAMHSA collection requirements is potentially significant.

Split Sample Rights: Your Right to an Independent Retest

Under federal workplace testing regulations, every urine specimen is split into two bottles at collection: the primary specimen (Bottle A) used for initial testing, and the split specimen (Bottle B) frozen and held by the lab. If you dispute a confirmed positive result, you have the legal right to request that Bottle B be sent to a different SAMHSA-certified laboratory for independent GC-MS analysis at your expense. The MRO is required to notify you of this right when reporting a positive. The request must typically be made within 72 hours of the MRO’s notification call.

The split specimen retest uses the same confirmation cutoffs and GC-MS methodology. If Bottle B tests negative, the MRO must cancel the result. If Bottle B also tests positive, the positive stands and your recourse shifts to administrative or legal challenge of the procedure. Independent confirmation is the fastest and most direct way to resolve a disputed result, and it is particularly valuable in cases involving potential cross-reactivity or laboratory error.

Reading a Lab Report: What the Numbers Mean

If you receive a formal laboratory report rather than a simple pass/fail notification, understanding the reported values helps you contextualize the result. A typical cannabis urine immunoassay report will show the analyte (THC-COOH), the cutoff used (e.g., 50 ng/mL), and either a quantitative result or a qualitative positive/negative designation. GC-MS confirmation reports will show the quantitative concentration in ng/mL alongside the confirmation cutoff and the instrument identification.

A report showing “THC-COOH: 73 ng/mL (cutoff: 50 ng/mL) — POSITIVE” means the metabolite was detected at 73 ng/mL, which exceeds the 50 ng/mL threshold. This then proceeds to GC-MS confirmation. A confirmation report showing “THC-COOH confirmed: 18 ng/mL (confirmation cutoff: 15 ng/mL) — CONFIRMED POSITIVE” means the specific molecule was identified at 18 ng/mL, exceeding the confirmation threshold. Both thresholds must be exceeded for a result to be reported as a confirmed positive by the MRO.

How to Dispute a Positive Result: Step-by-Step

If you receive a positive drug test result that you believe is in error, here is the practical process for disputing it in a federal or regulated workplace testing program:

1. Do not panic or resign. You have procedural rights. The employer cannot take adverse action until the MRO process is complete.
2. Request the split specimen retest within 72 hours of the MRO’s call. State this clearly and in writing if possible.
3. Compile medication documentation. Gather prescriptions, pharmacy printouts, and a letter from your prescribing physician for any relevant medications taken in the past 60 days.
4. Present documentation to the MRO. During the interview, provide the complete list and supporting documentation. The MRO has authority to cancel a result if a legitimate medical explanation is supported by documentation.
5. If the MRO upholds the positive, consult an employment attorney in your state. Many states have enacted employee protections for off-duty cannabis use that may apply to your situation.
6. Request the complete chain-of-custody record through your attorney. Any procedural deviation from SAMHSA standards can be grounds for challenge in administrative proceedings.